Brief Pain Exposure Therapy (BPET) for Nociplastic Pain

Inclusion Criteria:

• Able to read, write and speak English

• Internet access and audio-visual conferencing capability (e.g., Zoom meetings byphone or computer) in the home

Fibromyalgia participants must have:

• Physician diagnosis of fibromyalgia

• OR: meet 2016 American College of Rheumatology (ACR) Criteria for FM: Widespreadpain index score is ≥ 7 and symptom severity scale score is ≥ 5, or widespread painindex score is 4 to 6 and symptom severity score is ≥ 9

• OR: have pain self-reported in 4 out of 7 body regions in the General SensorySensitivity (GSS)-brief body map AND Opioid Use Disorder diagnosis by a physician.

Lupus participants must have:

• Physician diagnosis of systemic lupus erythematosus

• AND: Have pain self-reported in 4 out of 7 body regions in the GSS-brief body map

• AND: No change in medications or steroid dose for one month prior to entry (to avoidoscillation of steroid dosing during the study due to active disease).

Exclusion Criteria:

• Indication of a co-occurring (non-fibromyalgia OR non-lupus) cause of chronic pain (e.g., inflammatory arthritis, other autoimmune disorders, spinal cord injury,cancer)

• Currently receiving cognitive-behavioral therapy or other psychological therapiesfor pain

• Open litigation regarding chronic pain in the past 1 year, as assessed inpreliminary study screening.

• Inability to provide informed consent and complete study procedures (e.g.,indications of suspected major cognitive impairment via observations of study staffduring consenting) that would preclude comprehension or participation in studyprotocols.

• Pregnant or breastfeeding

• Any other diseases or conditions that would make a patient unsuitable for studyparticipation as determined by the site principal investigators.

• Lupus group only: taking >10 mg prednisone (or equivalent steroid) dose per day asan indicator of ongoing disease activity (with no other strict exclusions based onmedications)